View Item 

Show simple item record

Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies
dc.contributor.authorParnes, Aric
dc.contributor.authorMahlangu, Johnny N.
dc.contributor.authorPipe, Steven W.
dc.contributor.authorPaz‐priel, Ido
dc.contributor.authorLehle, Michaela
dc.contributor.authorTrask, Peter C.
dc.contributor.authorJiménez‐yuste, Víctor
dc.date.accessioned2021-12-02T02:30:00Z
dc.date.available2022-12-01 21:29:58en
dc.date.available2021-12-02T02:30:00Z
dc.date.issued2021-11
dc.identifier.citationParnes, Aric; Mahlangu, Johnny N.; Pipe, Steven W.; Paz‐priel, Ido ; Lehle, Michaela; Trask, Peter C.; Jiménez‐yuste, Víctor (2021). "Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies." Haemophilia 27(6): e772-e775.
dc.identifier.issn1351-8216
dc.identifier.issn1365-2516
dc.identifier.urihttps://hdl.handle.net/2027.42/170992
dc.publisherUS Food & Drug Administration
dc.publisherWiley Periodicals, Inc.
dc.titlePatient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/170992/1/hae14421.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/170992/2/hae14421_am.pdf
dc.identifier.doi10.1111/hae.14421
dc.identifier.sourceHaemophilia
dc.identifier.citedreferenceRummel M, Kim TM, Aversa F, et al. Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B- cell lymphoma or follicular lymphoma: results from a prospective, randomized, open- label, crossover study (PrefMab). Ann Oncol. 2017; 28 ( 4 ): 836 - 842.
dc.identifier.citedreferenceKempton C, Trask P, Parnes A, et al. Development and testing of the satisfaction questionnaire with intravenous or subcutaneous hemophilia injection and results from the phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors. Haemophilia. 2021; 27 ( 2 ): 221 - 228.
dc.identifier.citedreferenceOldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017; 377 ( 9 ): 809 - 818.
dc.identifier.citedreferenceYoung G, Liesner R, Chang T, et al. A multicenter, open- label, phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019; 134 ( 24 ): 2127 - 2138.
dc.identifier.citedreferenceMahlangu J, Oldenburg J, Paz- Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018; 379 ( 9 ): 811 - 822.
dc.identifier.citedreferencePipe S, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open- label, non- randomised phase 3 study. Lancet Haematol. 2019; 6 ( 6 ): E295 - E305.
dc.identifier.citedreferenceO’Mahony B, Skinner MW, Noone D, Page D, O’Hara J. Assessments of outcome in haemophilia - a patient perspective. Haemophilia. 2016; 22 ( 3 ): e208 - e209.
dc.identifier.citedreferenceUS Food & Drug Administration. The Voice of the Patient: Hemophilia A, Hemophilia B, von Willebrand Disease and Other Heritable Bleeding Disorders. US Food & Drug Administration; 2016; https://www.fda.gov/files/about%20fda/published/The- Voice- of- the- Patient- - Hemophilia- A- - Hemophilia- B- - von- Willebrand- Disease- and- Other- Heritable- Bleeding- Disorders.pdf Accessed: 27 Sept 2021.
dc.identifier.citedreferenceWiley RE, Khoury CP, Snihur AWK, et al. From the voices of people with haemophilia A and their caregivers: challenges with current treatment, their impact on quality of life and desired improvements in future therapies. Haemophilia. 2019; 25 ( 3 ): 433 - 440.
dc.identifier.citedreferenceEscudier B, Porta C, Bono P, et al. Randomized, controlled, double- blind, cross- over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol. 2014; 32 ( 14 ): 1412 - 1418.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
hae14421.pdf
Size:
563.2KB
Format:
PDF
View/Open
Name:
hae14421_am.pdf
Size:
789.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.